The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.
 
Joy X. Jarnagin
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Foundation Medicine; Lilly; Natera; PureTech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); Tesaro (Inst)
 
Emily E. Van Seventer
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Yojan Shah
No Relationships to Disclose
 
Islam Baiev
No Relationships to Disclose
 
Amirkasra Mojtahed
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Jeffrey William Clark
Research Funding - Pfizer (Inst)
 
Joseph Wang Franses
Stock and Other Ownership Interests - Biogen; Merck
Consulting or Advisory Role - Foundation Medicine
 
Bruce J. Giantonio
No Relationships to Disclose
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst)
Other Relationship - NCCN
 
Eric Roeland
Consulting or Advisory Role - AIM Specialty Health; Asahi Kasei; Astellas Pharma; BASF; Helsinn Therapeutics; HERON; Napo Pharmaceuticals; Oragenics; Oragenics; Pfizer/EMD Serono; Vector Oncology
Expert Testimony - Regents of the University of California
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Exact Sciences; MPM Capital; Thrive Earlier Detection Corp
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - Gritstone Bio; Maverick Therapeutics; MPM Capital; Oncorus; TCR2 Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
Expert Testimony - Boehringer Ingelheim
Other Relationship - TCR2 Therapeutics
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly; Merrimack
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Abbvie; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly
 
Giulia Siravegna
No Relationships to Disclose
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; C4 Therapeutics; Fount Therapeutics; Kinnate Biopharma; nRichDx; Revolution Medicines
Consulting or Advisory Role - Abbvie; Amgen; Array BioPharma; Asana Biosciences; Astex Pharmaceuticals; Avidity Nanomedicines; Bristol-Myers Squibb; C4 Therapeutics; Chugai Pharma; Elicio Therapeutics; FOGPharma; Fount Therapeutics; Genentech; Ipsen; Kinnate Biopharma; Loxo; Merrimack; N-of-One; Natera; Novartis; nRichDx; Revolution Medicines; Roche; Roivant; Shionogi; Shire; Spectrum Pharmaceuticals; Symphogen; Taiho Pharmaceutical; Warp Drive Bio; Zikani Therapeutics
Research Funding - Asana Biosciences; AstraZeneca; Lilly; Sanofi
 
Ryan David Nipp
No Relationships to Disclose